Vincent Charlon joined Anergis in January 2009 as Chief Executive Officer (CEO). Dr Charlon brings over 20 years of global clinical development and management experience. From 1990 to 1998, at Hoffmann La Roche Basel as Clinical Research Scientist and then at Hoffmann La Roche Inc. Nutley,USA, as Director of Clinical Research, Dr Charlon held clinical development responsibilities for several international projects. He was the first author of an approved global new drug application for an anti-antihypertensive and anti-anginal new chemical entity and was involved in numerous meetings with the US FDA and European regulatory authorities. From 1998 to 2006, Vincent Charlon was CEO of Hesperion Ltd., the contract research organization (CRO) who designed and conducted all initial clinical trials for Actelion’s [SWX, ATLN] products. In this capacity, Vincent Charlon designed the first clinical trials of Tracleer® in pulmonary hypertension, today Actelion’s biggest product with sales well over CHF 1 billion/year. Vincent Charlon developed Hesperion as a profitable CRO from 3 to 200 employees located in eight country offices, serving over a hundred clients. Two third of Hesperion clients were small biotech companies from North America and Europe. During that time, Dr Charlon also realized two company acquisitions and integrations into Hesperion, as well as the sale of Hesperion to Cerep SA. In 2007-2008, Vincent Charlon was CEO of the drug repositioning start-up company LS Pharma International SA before joining Anergis.

 Clinical Research